focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,114.00
Bid: 12,116.00
Ask: 12,122.00
Change: -58.00 (-0.48%)
Spread: 6.00 (0.05%)
Open: 12,180.00
High: 12,188.00
Low: 12,096.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: Jefferies cuts Persimmon; BoA cuts GSK

Mon, 05th Dec 2022 10:00

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

----------

FTSE 100

----------

Bank of America cuts Vodafone price target to 130 (140) pence - 'neutral'

----------

Bank of America cuts BT Group price target to 187 (223) pence - 'buy'

----------

Bank of America cuts GSK to 'underperform' (neutral) - price target 1,450 (1,640) pence

----------

Bank of America raises AstraZeneca price target to 14,500 (12,500) pence - 'buy'

----------

Bernstein cuts Reckitt Benckiser price target to 6,100 (6,400) pence - 'market-perform'

----------

Bernstein cuts Unilever to 'market-perform' (outperform) - price target 3,500 (4,280) pence

----------

RBC raises Compass Group price target to 1,625 (1,575) pence - 'underperform'

----------

JPMorgan raises B&M price target to 555 (414) pence - 'overweight'

----------

JPMorgan raises Sainsbury price target to 206 (161) pence - 'underweight'

----------

JPMorgan raises Tesco price target to 270 (240) pence - 'overweight'

----------

Jefferies raises Barratt Developments price target to 452 (356) pence - 'hold'

----------

Jefferies cuts Persimmon to 'hold' (buy) - price target 1,436 (1485) pence

----------

Jefferies raises Taylor Wimpey price target to 124 (105) pence - 'buy'

----------

Jefferies raises Berkeley Group price target to 4,554 (4,330) pence - 'buy'

----------

Jefferies raises CRH price target to 51.60 (50.30) EUR - 'buy'

----------

Jefferies cuts Spirax-Sarco price target to 9,910 (11,460) pence - 'underperform'

----------

FTSE 250

----------

Bank of America raises Helios Towers price target to 180 (175) pence - 'buy'

----------

Morgan Stanley cuts Hays price target to 145 (146) pence - 'overweight'

----------

Morgan Stanley cuts PageGroup to 'equal-weight' (overweight) - price target 505 (510) pence

----------

UBS raises easyJet price target to 600 (565) pence - 'buy'

----------

Jefferies raises Travis Perkins price target to 931 (811) pence - 'hold'

----------

Jefferies raises Redrow price target to 592 (491) pence - 'buy'

----------

Jefferies raises Crest Nicholson price target to 278 (229) pence - 'buy'

----------

Jefferies raises Vistry price target to 829 (744) pence - 'buy'

----------

Jefferies raises Bellway to 'buy' (hold) - price target 2,458 (1,928) pence

----------

SMALL CAP

----------

Citigroup cuts Gamma Communications price target to 1,320 (1,650) pence - 'buy'

----------

Berenberg raises Tharisa price target to 260 (240) pence - 'buy'

----------

Deutsche Bank cuts Ferguson price target to 9,630 (9,960) pence - 'hold'

----------

Barclays raises AIB price target to 3.80 (3.40) EUR - 'equal weight'

----------

Jefferies cuts Watkin Jones to 'hold' (buy) - price target 111 (225) pence

----------

Jefferies cuts Kingspan to 'underperform' (hold) - price target 45.90 (63.60) EUR

----------

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.